196
Views
14
CrossRef citations to date
0
Altmetric
CASE REPORT

A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome

, , , , , , , , & show all
Pages 281-285 | Received 12 Jun 2013, Accepted 15 Oct 2013, Published online: 02 Dec 2013

References

  • Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 2002;13(1):140–9.
  • Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756–67.
  • Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008.
  • Alizadeh AA, Advani RH. Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clin Adv Hematol Oncol. 2008;6(12):899–909.
  • Kevil CG, Payne DK, Mire E, Alexander JS. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem. 1998;273(24):15099–103.
  • Niitsu N, Okamato M, Nakamine H, Yoshino T, Tamaru J, Nakamura S, et al. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol. 2002;68(2):91–100.
  • Zhao WL, Mourah S, Mounier N, Leboeuf C, Daneshpouy ME, Legrès L, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest. 2004;84(11):1512–9.
  • Konstantinou K, Yamamoto K, Ishibashi F, Mizoguchi Y, Kurata M, Nakagawa Y, et al. Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma. Br J Haematol. 2009;144(5):696–704.
  • Ratajczak P, Leboeuf C, Wang L, Brière J, Loisel-Ferreira I, Thiéblemont C, et al. BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma. Mod Pathol. 2012;25(6):805–14.
  • Arima K, Origuchi T, Tamai M, Iwanaga N, Izumi Y, Huang M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653–5.
  • McCarty DJ, O’Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA. 1985;254(19):2763–7.
  • de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol. 2010;148(5):673–89.
  • Sekine R, Ohno N, Uchimura K, Oyaizu N, Tojo A. Severe systemic edema correlated with serum VEGF titer in a patient with angioimmunoblastic T-cell lymphoma (in Japanese). Rinsho Ketsueki. 2007;48(11):1498–502.
  • Russell EB. Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia. J Rheumatol. 2005;32(9):1760–1.
  • Olivé A, del Blanco J, Pons M, Vaquero M, Tena X. The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalán Group for the Study of RS3PE. J Rheumatol. 1997;24(2):333–6.
  • Bucaloiu ID, Olenginski TP, Harrington TM. Remitting seronegative symmetrical synovitis with pitting edema syndrome in a rural tertiary care practice: a retrospective analysis. Mayo Clin Proc. 2007; 82(12):1510–5.
  • Olivieri I, Salvarani C, Cantini F. RS3PE syndrome: an overview. Clin Exp Rheumatol. 2000;18(4 Suppl 20):S53–5.
  • Goldenberg K, Rozenbaum M, Rosner I, Naschitz J, Kotler C. Remitting symmetric seronegative synovitis with pitting edema (RS3PE) secondary to non-Hodgkin's lymphoma. Clin Exp Rheumatol. 1998;16(6):767–8.
  • Yamasaki T, Takeoka Y, Nakao Y, Fusamoto H. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome with malignant lymphoma. Nihon Naika Gakkai Zasshi. 2002;91(3):1031–3.
  • Paira S, Graf C, Roverano S, Rossini J. Remitting seronegative symmetrical synovitis with pitting oedema: a study of 12 cases. Clin Rheumatol. 2002;21(2):146–9.
  • Roldan MR, Martinez F, Roman J, Torres A. Non-Hodgkin's lymphoma: initial manifestation. Ann Rheum Dis. 1993;52(1):85–6.
  • Gisserot O, Crémades S, Landais C, Leyral G, Bernard P, de Jauréguiberry JP. RS3PE revealing recurrent non-Hodgkin's lymphoma. Joint Bone Spine. 2004;71(5):424–6.
  • Baronio M, Cerudelli B, Cappelli C, Pascarella A, Airò P. Remitting symmetric seronegative synovitis with pitting edema associated with B-cell non-Hodgkin's lymphoma. Clin Exp Rheumatol. 2000;18(6):787.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.